1. Home
  2. AOD vs EYPT Comparison

AOD vs EYPT Comparison

Compare AOD & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo abrdn Total Dynamic Dividend Fund of Beneficial Interest

AOD

abrdn Total Dynamic Dividend Fund of Beneficial Interest

HOLD

Current Price

$10.30

Market Cap

1.1B

Sector

Finance

ML Signal

HOLD

EYPT

EyePoint Pharmaceuticals Inc.

HOLD

Current Price

$12.55

Market Cap

1.3B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
AOD
EYPT
Founded
N/A
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Laboratory Analytical Instruments
Sector
Finance
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.3B
IPO Year
2006
2005

Fundamental Metrics

Financial Performance
Metric
AOD
EYPT
Price
$10.30
$12.55
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$31.80
AVG Volume (30 Days)
439.2K
920.7K
Earning Date
01-01-0001
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$7,539,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$3,115.57
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.51
$8.37
52 Week High
$10.77
$19.11

Technical Indicators

Market Signals
Indicator
AOD
EYPT
Relative Strength Index (RSI) 47.51 48.33
Support Level $10.24 $12.58
Resistance Level $10.28 $14.73
Average True Range (ATR) 0.17 0.75
MACD -0.06 -0.02
Stochastic Oscillator 41.73 48.53

Price Performance

Historical Comparison
AOD
EYPT

About AOD abrdn Total Dynamic Dividend Fund of Beneficial Interest

Aberdeen Total Dynamic Dividend Fund is a diversified, closed-end management investment company. Its investment objective is to seek high current dividend income. The company also focuses on the long-term growth of capital as a secondary investment objective. The fund invests in foreign securities, including direct investments in securities of foreign issuers and investments in depositary receipts that represent indirect interests in securities of foreign issuers. Its portfolio consists of securities from Information Technology, Financial, Healthcare, and Industrials among other sectors.

About EYPT EyePoint Pharmaceuticals Inc.

EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.

Share on Social Networks: